Structure Therapeutics begins enrolling two Phase 3 trials of oral GLP-1 pill aleniglipron
An oral GLP-1 pill from Structure Therapeutics is now in two large Phase 3 trials, but results are not due until 2028 and no approval date has been set.
Structure Therapeutics has started enrolling participants in two Phase 3 trials of aleniglipron, an experimental oral GLP-1 medicine, under a program called ACCOMPLISH. ACCOMPLISH-1 is planned for about 3,600 participants, and ACCOMPLISH-2 for about 1,100. Enrollment in the two studies opened within days of each other [1][2].
Phase 3 is the last stage of human testing before a company can ask the FDA to approve a medicine. The first results from these trials, known as topline results, are expected in the second half of 2028 [1][2]. Aleniglipron is not approved for any use and is not available outside clinical trials [1][2].
Aleniglipron is a small-molecule GLP-1 receptor agonist taken as a pill rather than an injection [1][2]. It belongs to the same broad drug class as semaglutide, sold as Ozempic, Wegovy and Rybelsus, and tirzepatide, sold as Mounjaro and Zepbound. Most GLP-1 medicines on the US market are given by injection.
The two trials are different sizes, with the larger study planned for roughly three times as many participants as the smaller one [1][2]. How the two studies differ in the groups they enroll, the doses they test, or the outcomes they measure has not been disclosed. Also not disclosed: whether either trial compares aleniglipron against a placebo or against an approved GLP-1 medicine, what dose or dosing schedule is used, what body weight or health conditions participants must have to join, or where the trials are running [1][2].
Aleniglipron is one of several oral small-molecule GLP-1 candidates in late-stage development. Orforglipron, made by Eli Lilly and sold under the brand name Foundayo, is another. No head-to-head comparison between aleniglipron and orforglipron has been reported.
Why it matters for patients
For people who take a GLP-1 medicine or are considering one, a pill option in Phase 3 testing matters mainly as a possible future choice. An oral GLP-1 could appeal to people who want to avoid injections, but aleniglipron is years away from any possible US pharmacy shelf: results are not expected until the second half of 2028, and an FDA review would come after that if the company chooses to file [1][2].
Being in Phase 3 is not a guarantee. Some medicines that reach this stage fail to show enough benefit, or show side effects that make approval unlikely. Nothing in the trial listings shows how well aleniglipron works or how it compares with semaglutide or tirzepatide, and no information on price, insurance coverage or supply has been released. Because the trials are enrolling now, people who are interested in research can ask their own doctor about study participation, though the eligibility criteria for these two trials have not been detailed here [1][2].
What happens next
Both studies are listed as enrolling [1][2]. The next scheduled milestone is topline data from ACCOMPLISH-1 and ACCOMPLISH-2, expected in the second half of 2028 [1][2]. No date for an FDA submission or a possible approval decision has been announced.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.